Literature DB >> 25451824

Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?

Nicolas Barry Delongchamps1, Arnaud Lefèvre2, Naïm Bouazza3, Frédéric Beuvon4, Paul Legman2, François Cornud2.   

Abstract

PURPOSE: Magnetic resonance imaging-transrectal ultrasound fusion targeted prostate biopsies were suggested to detect significant cancer with more accuracy than systematic biopsies. In this study we evaluate the pathological characteristics of multiparametric magnetic resonance imaging detected and undetected tumor foci on radical prostatectomy specimens.
MATERIALS AND METHODS: We selected 125 consecutive patients treated with radical prostatectomy for clinically localized prostate cancer diagnosed on magnetic resonance imaging-transrectal ultrasound targeted biopsy and/or systematic biopsy. On multiparametric magnetic resonance imaging each suspicious area was graded according to the PI-RADS score. On radical prostatectomy specimen, tumor foci with a Gleason score greater than 3+3 and/or tumor volume greater than 0.5 ml were considered significant. A correlation analysis between multiparametric magnetic resonance imaging and pathological findings was performed.
RESULTS: Pathological analysis of radical prostatectomy specimens detected 230 tumor foci. Of these, 137 were considered significant (Gleason score greater than 3+3 in 112) and were observed in 111 (89%) glands. A total of 95 individual tumor foci, including 14 significant foci, were missed with multiparametric magnetic resonance imaging. All of them were located in glands where another focus was detected with multiparametric magnetic resonance imaging. An additional 9 individual tumor foci, including 7 significant, were detected on multiparametric magnetic resonance imaging but missed with targeted biopsy, resulting in 5 (4%) significant cancers undetected with magnetic resonance imaging-transrectal ultrasound fusion targeted biopsy. The magnetic resonance imaging target largest diameter was associated with high volume (greater than 0.5 cc) foci detection, while PI-RADS score and cancer involvement on targeted biopsy were associated with significant foci detection.
CONCLUSIONS: In these series of men with suspicious prostate multiparametric magnetic resonance imaging findings, magnetic resonance imaging-transrectal ultrasound fusion guided targeted biopsy alone strategy would have resulted in the under detection of only 4% significant cancers.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; early detection of cancer; prostatic neoplasms

Mesh:

Year:  2014        PMID: 25451824     DOI: 10.1016/j.juro.2014.11.002

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].

Authors:  C Kesch; J P Radtke; F Distler; S Boxler; T Klein; C Hüttenbrink; K Hees; W Roth; M Roethke; H P Schlemmer; M Hohenfellner; B A Hadaschik
Journal:  Urologe A       Date:  2016-08       Impact factor: 0.639

2.  Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms.

Authors:  N Westhoff; F P Siegel; D Hausmann; M Polednik; J von Hardenberg; M S Michel; M Ritter
Journal:  World J Urol       Date:  2016-11-09       Impact factor: 4.226

3.  Association of training level and outcome of software-based image fusion-guided targeted prostate biopsies.

Authors:  Niklas Westhoff; Henning Haumann; Maximilian Christian Kriegmair; Jost von Hardenberg; Johannes Budjan; Stefan Porubsky; Maurice Stephan Michel; Patrick Honeck; Manuel Ritter
Journal:  World J Urol       Date:  2018-12-17       Impact factor: 4.226

4.  Diffusion-weighted imaging of the prostate: should we use quantitative metrics to better characterize focal lesions originating in the peripheral zone?

Authors:  Thibaut Pierre; Francois Cornud; Loïc Colléter; Frédéric Beuvon; Frantz Foissac; Nicolas B Delongchamps; Paul Legmann
Journal:  Eur Radiol       Date:  2017-11-22       Impact factor: 5.315

5.  Robotic-assisted transrectal MRI-guided biopsy. Technical feasibility and role in the current diagnosis of prostate cancer: an initial single-center experience.

Authors:  Joan C Vilanova; Anna Pérez de Tudela; Josep Puig; Martijn Hoogenboom; Joaquim Barceló; Montse Planas; Sònia Sala; Santiago Thió-Henestrosa
Journal:  Abdom Radiol (NY)       Date:  2020-07-23

6.  Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.

Authors:  Daniel I Glazer; Elmira Hassanzadeh; Andriy Fedorov; Olutayo I Olubiyi; Shayna S Goldberger; Tobias Penzkofer; Trevor A Flood; Paul Masry; Robert V Mulkern; Michelle S Hirsch; Clare M Tempany; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2017-03

7.  Evaluation of the 'Prostate Interdisciplinary Communication and Mapping Algorithm for Biopsy and Pathology' (PIC-MABP).

Authors:  Daniel Junker; Thomas R W Herrmann; Markus Bader; Jasmin Bektic; Gregor Henkel; Stephan Kruck; Markus Sandbichler; David Schilling; Georg Schäfer; Udo Nagele
Journal:  World J Urol       Date:  2015-07-01       Impact factor: 4.226

8.  Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.

Authors:  J P Radtke; T H Kuru; D Bonekamp; M T Freitag; M B Wolf; C D Alt; G Hatiboglu; S Boxler; S Pahernik; W Roth; M C Roethke; H P Schlemmer; M Hohenfellner; B A Hadaschik
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-17       Impact factor: 5.554

9.  Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use.

Authors:  Jelle O Barentsz; Jeffrey C Weinreb; Sadhna Verma; Harriet C Thoeny; Clare M Tempany; Faina Shtern; Anwar R Padhani; Daniel Margolis; Katarzyna J Macura; Masoom A Haider; Francois Cornud; Peter L Choyke
Journal:  Eur Urol       Date:  2015-09-08       Impact factor: 20.096

Review 10.  Magnetic Resonance-Guided Prostate Ablation.

Authors:  David A Woodrum; Akira Kawashima; Krzysztof R Gorny; Lance A Mynderse
Journal:  Semin Intervent Radiol       Date:  2019-12-02       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.